Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 01/03/2022

    CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer®

    The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
  • Press release - 10/02/2022

    CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-participant-phase-1-study-multivalent-influenza-vaccine-candidate-based-second-generation-mrna-backbone-deve
  • Dossier - 16/12/2021 In-vivo-Gentherapien wie Zolgensma und Ex-vivo-Gentherapien wie CAR-T-Zellen.

    Advanced therapy medicinal products: gene and cell therapies

    Novel gene and cell therapies for treating incurable and hereditary diseases have raised high expectations. However, success has so far been limited to the long-established bone marrow transplants involving the administration of haematopoietic stem cells used to treat blood cancer. CAR T-cell therapies have recently emerged as a major new hope in cancer treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/advanced-therapy-medicinal-products-gene-and-cell-therapies
  • Press release - 25/11/2021

    New Collaborative Research Centre at Ulm University Focusing on the factors that influence human aging

    After a highly competitive process Ulm University has been awarded its fifth Collaborative Research Centre (CRC). The new CRC 1506 ‘Aging at Interfaces’ addresses one of the most urgent medical challenges of our time: the aging of the human body and the diseases and constraints that are frequently associated with the aging process.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-collaborative-research-centre-ulm-university-focusing-factors-influence-human-aging
  • Press release - 23/11/2021

    Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response

    At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
  • Press release - 16/11/2021

    Cystic fibrosis & COPD: Mucus reprograms immune cells and promotes airway inflammation

    Scientists of the Translational Lung Research Center Heidelberg (TLRC) and the German Cancer Research Center (DKFZ) have discovered a new link between excessive airway mucus and chronic airway inflammation that is characteristic of cystic fibrosis and chronic obstructive pulmonary disease (COPD). The researchers showed that mucus in the airways reprograms certain cells of the immune system.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cystic-fibrosis-copd-mucus-reprograms-immune-cells-and-promotes-airway-inflammation
  • Press release - 15/11/2021

    Using T cells to target malignant brain tumors

    Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
  • Press release - 13/10/2021

    Tackling the collateral damage from antibiotics

    EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tackling-collateral-damage-antibiotics
  • Press release - 12/10/2021

    CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-shift-focus-covid-19-vaccine-development-second-generation-mrna-technology
  • Press release - 02/09/2021

    Award-winning science: Cancer-promoting metabolic pathways as targets of new therapies

    Christiane Opitz, scientist at the German Cancer Research Center, is being awarded this year's Ita Askonas Prize of the European Federation of Immunological Societies. Opitz has discovered how tumor cells use certain metabolites to protect themselves against the immune system. Her research findings may provide important clues for the development of new therapeutic concepts.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/award-winning-science-cancer-promoting-metabolic-pathways-targets-new-therapies
  • Press release - 13/08/2021

    Paradigm shift in immunology 'Adaptive Tolerance' balances autoimmune reaction

    Immunologists at Ulm University and its Medical Centre have developed a new model that could revolutionise the treatment of autoimmune disease as well as vaccine development. As 'Adaptive Tolerance' demonstrates, autoreactive antibodies are by no means disease drivers which a healthy organism swiftly eliminates. Rather, they trigger the formation of a class of antibodies that protect the body's own structures.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/paradigm-shift-immunology-adaptive-tolerance-balances-autoimmune-reaction
  • Press release - 26/07/2021

    Vaccination against hereditary colorectal cancer successful in mice

    Scientists from the German Cancer Research Center and Heidelberg University Hospital have for the first time been able to delay the development of hereditary colorectal cancer with a protective vaccination. Mice with a hereditary predisposition to colorectal cancer survived significantly longer after vaccination than unvaccinated animals. Combining the vaccination with an anti-inflammatory drug increased the protective effect.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-against-hereditary-colorectal-cancer-successful-mice
  • Article - 10/06/2021 DSC3962.jpg

    New study: vaccine therapy for treating patients with chronic leukaemia

    Personalised peptide vaccination is expected to improve the treatment of patients with chronic lymphocytic leukaemia. A research team from Tübingen has started a Phase I clinical trial with CLL patients who will undergo ibrutinib treatment. Other leukaemia sufferers as well as cancer patients in general are also expected to benefit in the long term.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-study-vaccine-therapy-treating-patients-chronic-leukaemia
  • Press release - 25/05/2021

    How “paralyzed” immune cells can be reactivated against brain tumors

    Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpg

    Vaccines – a beacon of hope in the fight against pandemics

    Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology. The development of much-needed vaccines against many other…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Press release - 20/05/2021

    Immune cells promote proinflammatory fatty liver disease

    A particular type of dendritic cell is responsible for the tissue damage that occurs in non-alcoholic steatohepatits (NASH) in mice and humans. The dendritic cells cause aggressive, proinflammatory behavior in T cells, as now discovered by researchers from the German Cancer Research Center (DKFZ) in collaboration with colleagues from Israeli research institutes. Blocking these dendritic cells alleviates symptoms in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-cells-promote-proinflammatory-fatty-liver-disease
  • Article - 29/04/2021 aufbau-antikoerper.jpg

    Nanobodies for determining neutralising antibodies after corona infection

    After contact with a pathogen, ideally our immune system generates neutralising antibodies to prevent a future infection. With NeutrobodyPlex, scientists from Reutlingen and Tübingen have developed a highly specific test procedure based on single-domain antibodies (nanobodies) that can be used to easily and reliably determine the quality of the immune response against the novel coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nanobodies-determining-neutralising-antibodies-after-corona-infection
  • Press release - 14/04/2021

    Engineering T cells for cancer therapy efficiently and safely

    Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/engineering-t-cells-cancer-therapy-efficiently-and-safely
  • Press release - 23/03/2021

    CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrates-protection-against-sars-cov-2-b1351-variant-south-african-variant-precli
  • Press release - 04/03/2021

    CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-novartis-sign-initial-agreement-manufacturing-covid-19-vaccine-candidate-cvncov
  • Press release - 03/03/2021

    New Baden-Württemberg network to reduce animal experiments

    A new network has been set up in Baden-Württemberg aimed at reducing animal experiments as well as further improving animal welfare. It combines new approaches and measures at the state’s biomedical research locations, which are expected to limit stress in laboratory animals and steadily reduce the number of animals used in research in line with the 3R principles of Replacement, Reduction, and Refinement.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-baden-wuerttemberg-network-reduce-animal-experiments
  • Press release - 01/02/2021

    Targeting a rapid market breakthrough for new vaccine production method

    In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
  • Press release - 01/12/2020

    Novel vaccine trial to activate T-cell responses against SARS-CoV-2

    A Phase I clinical trial using a self-developed vaccine against SARS-CoV-2 was initiated today at the University Hospital of Tübingen. In contrast to the currently evaluated vaccine candidates against COVID-19, the vaccine CoVAC1, developed by the Department of Immunology (Director Prof. Hans-Georg Rammensee) at the University of Tübingen, aims specifically at the induction of a T-cell-mediated immune response against SARS-COV-2.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/Novel-vaccine-trial-to-activate-T-cell-responses-against-SARS-CoV-2
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial – with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Intestinal peptide heals lung - 14/10/2020 Die Immuntherapie (ICI)  aktiviert Effektor-T-Zellen  und reduziert auf der anderen Seite regulatorische T-zellen, um den Tumor zu besiegen (schwarze Zellen). Die durch die Immuntherapie ausgelöste Lungenentzündung wird mit Steroidtherapie (Cortison) oder mit inhaliertem VIP (vasoaktives intestinales Peptid) behandelt. Unter VIP kommt es zur Dämpfung der Entzündung.

    Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia

Page 1 / 8

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search